Ureteral Stent-Related Symptom

3

Review clinical trials related to Ureteral Stent-Related Symptom. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Dexamethasone for Ureteral STent Symptoms (DUSTS)

The purpose of this study to learn if high-dose dexamethasone, a type of long-acting steroid, works to decrease urinary symptoms and pain after ureteroscopy and stent placement for kidney stones. The main question it aims to answer is: 1\) Does high-dose steroid change the quality of life score on day 2 after surgery Researchers will compare high-dose of dexamethasone (20 mg) to a standard dose of dexamethasone (4 mg) to see if a higher dose of the drug will help with urinary symptoms and pain Participants will: 1. randomly receive 20 mg or 4 mg of dexamethasone (20 mg) at the time of surgery 2. fill out a questionnaire day 1 and day 2 after surgery 3. fill out a medication diary for one week after surgery 4. visit the clinic on day 2 after surgery for checkup 5. visit the clinic on day 4-7 after surgery for check up

Participants needed: 70
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: The Methodist Hospital Research InstituteUpdated: May 29, 2026Locations: 1
Eligibility criteria

Age 18-70 years old [+3]

Untreated UTI [+15]

Status: Not yet recruiting

Stent Related Symptoms Defined by Ureteral Stent Symptom Questionnaire in Patients With Image-Informed Ureteral Stent Lengths

Placement of a ureteral stent at the end of ureteroscopy is commonly performed in endourology. The purpose of this study is to determine whether ureteral stents whose lengths are calibrated to a participant's specific ureteral length based on imaging are better tolerated than one-size-fits-all variable length ureteral stents. The investigators hypothesize that ureteral stent lengths calibrated to the ureteral length of each participant will be better tolerated.

Participants needed: 128
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Weill Medical College of Cornell UniversityUpdated: May 12, 2026Locations: 1
Eligibility criteria

Male or female age 18-80 years [+4]

Known urinary tract anatomical abnormality, reconstructed urinary system, or con... [+11]

Status: Recruiting

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

Participants needed: 189
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Bir HospitalUpdated: Sep 8, 2025Locations: 1
Eligibility criteria

Concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channe... [+11]